Implanet (ALIMP.PA) Stock Price

Implanet Price

Euronext·CLOSED
0.17EUR-0.0024 (-1.38 %)
Market closed

Revenue has compounded at 9.3% per year over the past 14 years to 9.41 M EUR. Implanet's net margin stands at -46.4%, up from -102.2% several years earlier. Analysts set a median price target of 2.00 EUR, implying 1,061.0% above the current price. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus. The stock trades about 19% above its 52-week low.

Implanet stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Implanet over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Implanet stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Implanet's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Implanet Stock Price History
DateImplanet Price
7/23/20260.17 EUR
7/22/20260.17 EUR
7/21/20260.17 EUR
7/20/20260.17 EUR
7/17/20260.18 EUR
7/16/20260.18 EUR
7/15/20260.18 EUR
7/14/20260.18 EUR
7/13/20260.18 EUR
7/10/20260.17 EUR
7/9/20260.18 EUR
7/8/20260.18 EUR
7/7/20260.18 EUR
7/6/20260.18 EUR
7/3/20260.18 EUR
7/2/20260.16 EUR
7/1/20260.16 EUR
6/30/20260.17 EUR
6/29/20260.17 EUR
6/26/20260.17 EUR
6/25/20260.16 EUR
6/24/20260.18 EUR
6/23/20260.18 EUR
6/22/20260.18 EUR
6/19/20260.19 EUR
6/18/20260.18 EUR
6/17/20260.18 EUR
6/16/20260.18 EUR
6/15/20260.19 EUR
6/12/20260.19 EUR
6/11/20260.19 EUR
6/10/20260.19 EUR
6/9/20260.19 EUR
6/8/20260.19 EUR
6/5/20260.19 EUR
6/4/20260.18 EUR
6/3/20260.18 EUR
6/2/20260.18 EUR
6/1/20260.18 EUR
5/29/20260.18 EUR
5/28/20260.19 EUR
5/27/20260.19 EUR
5/26/20260.19 EUR
5/25/20260.18 EUR
5/22/20260.19 EUR
5/21/20260.19 EUR
5/20/20260.19 EUR
5/19/20260.19 EUR
5/18/20260.19 EUR
5/15/20260.19 EUR
5/14/20260.19 EUR
5/13/20260.19 EUR
5/12/20260.20 EUR
5/11/20260.20 EUR
5/8/20260.18 EUR
5/7/20260.19 EUR
5/6/20260.19 EUR
5/5/20260.19 EUR
5/4/20260.19 EUR
4/30/20260.20 EUR
4/29/20260.20 EUR
4/28/20260.20 EUR
4/27/20260.20 EUR
4/24/20260.20 EUR
4/23/20260.21 EUR
4/22/20260.21 EUR
4/21/20260.21 EUR
4/20/20260.21 EUR
4/17/20260.21 EUR
4/16/20260.22 EUR
4/15/20260.23 EUR
4/14/20260.22 EUR
4/13/20260.22 EUR
4/10/20260.22 EUR
4/9/20260.22 EUR
4/8/20260.22 EUR
4/7/20260.22 EUR
4/2/20260.22 EUR
4/1/20260.22 EUR
3/31/20260.20 EUR
3/30/20260.20 EUR
3/27/20260.20 EUR
3/26/20260.20 EUR
3/25/20260.21 EUR
3/24/20260.21 EUR
3/23/20260.20 EUR
3/20/20260.21 EUR
3/19/20260.21 EUR
3/18/20260.22 EUR
3/17/20260.22 EUR
3/16/20260.22 EUR
3/13/20260.22 EUR
3/12/20260.22 EUR
3/11/20260.22 EUR
3/10/20260.22 EUR
3/9/20260.22 EUR
3/6/20260.22 EUR
3/5/20260.22 EUR
3/4/20260.23 EUR
3/3/20260.23 EUR
3/2/20260.23 EUR
2/27/20260.21 EUR
2/26/20260.20 EUR
2/25/20260.21 EUR
2/24/20260.23 EUR
2/23/20260.20 EUR
2/20/20260.20 EUR
2/19/20260.21 EUR
2/18/20260.22 EUR
2/17/20260.22 EUR
2/16/20260.23 EUR
2/13/20260.23 EUR
2/12/20260.23 EUR
2/11/20260.23 EUR
2/10/20260.23 EUR
2/9/20260.23 EUR
2/6/20260.23 EUR
2/5/20260.23 EUR
2/4/20260.23 EUR
2/3/20260.23 EUR
2/2/20260.23 EUR
1/30/20260.23 EUR
1/29/20260.23 EUR
1/28/20260.23 EUR
1/27/20260.24 EUR
1/26/20260.25 EUR
1/23/20260.25 EUR
1/22/20260.26 EUR
1/21/20260.24 EUR
1/20/20260.23 EUR
1/19/20260.24 EUR
1/16/20260.24 EUR
1/15/20260.23 EUR
1/14/20260.24 EUR
1/13/20260.25 EUR
1/12/20260.25 EUR
1/9/20260.24 EUR
1/8/20260.24 EUR
1/7/20260.24 EUR
1/6/20260.24 EUR
1/5/20260.25 EUR
1/2/20260.21 EUR
12/31/20250.20 EUR
12/30/20250.20 EUR
12/29/20250.20 EUR
12/24/20250.20 EUR
12/23/20250.19 EUR
12/22/20250.19 EUR
12/19/20250.21 EUR
12/18/20250.21 EUR
12/17/20250.25 EUR
12/16/20250.16 EUR
12/15/20250.16 EUR
12/12/20250.17 EUR
12/11/20250.17 EUR
12/10/20250.18 EUR
12/9/20250.18 EUR
12/8/20250.18 EUR
12/5/20250.19 EUR
12/4/20250.19 EUR
12/3/20250.19 EUR
12/2/20250.21 EUR
12/1/20250.22 EUR
11/28/20250.19 EUR
11/27/20250.20 EUR
11/26/20250.21 EUR
11/25/20250.21 EUR
11/24/20250.21 EUR
11/21/20250.21 EUR
11/20/20250.20 EUR
11/19/20250.20 EUR
11/18/20250.19 EUR
11/17/20250.20 EUR
11/14/20250.20 EUR
11/13/20250.20 EUR
11/12/20250.22 EUR
11/11/20250.24 EUR
11/10/20250.24 EUR
11/7/20250.24 EUR
11/6/20250.24 EUR
11/5/20250.25 EUR
11/4/20250.24 EUR
11/3/20250.25 EUR
10/31/20250.27 EUR
10/30/20250.27 EUR
10/29/20250.28 EUR
10/28/20250.27 EUR
10/27/20250.27 EUR
10/24/20250.26 EUR
10/23/20250.27 EUR
10/22/20250.27 EUR
10/21/20250.28 EUR
10/20/20250.26 EUR
10/17/20250.28 EUR
10/16/20250.29 EUR
10/15/20250.28 EUR
10/14/20250.28 EUR
10/13/20250.27 EUR
10/10/20250.29 EUR
10/9/20250.27 EUR
10/8/20250.35 EUR
10/7/20250.39 EUR
10/6/20250.41 EUR
10/3/20250.44 EUR
10/2/20250.43 EUR
10/1/20250.40 EUR
9/30/20250.40 EUR
9/29/20250.42 EUR
9/26/20250.35 EUR
9/25/20250.32 EUR
9/24/20250.31 EUR
9/23/20250.27 EUR
9/22/20250.28 EUR
9/19/20250.26 EUR
9/18/20250.28 EUR
9/17/20250.28 EUR
9/16/20250.32 EUR
9/15/20250.32 EUR
9/12/20250.31 EUR
9/11/20250.29 EUR
9/10/20250.30 EUR
9/9/20250.28 EUR
9/8/20250.29 EUR
9/5/20250.28 EUR
9/4/20250.30 EUR
9/3/20250.32 EUR
9/2/20250.30 EUR
9/1/20250.29 EUR
8/29/20250.19 EUR
8/28/20250.19 EUR
8/27/20250.19 EUR
8/26/20250.18 EUR
8/25/20250.19 EUR
8/22/20250.19 EUR
8/21/20250.19 EUR
8/20/20250.19 EUR
8/19/20250.19 EUR
8/18/20250.18 EUR
8/15/20250.18 EUR
8/14/20250.18 EUR
8/13/20250.18 EUR
8/12/20250.18 EUR
8/11/20250.17 EUR
8/8/20250.17 EUR
8/7/20250.17 EUR
8/6/20250.17 EUR
8/5/20250.17 EUR
8/4/20250.16 EUR
8/1/20250.17 EUR
7/31/20250.17 EUR
7/30/20250.18 EUR
7/29/20250.16 EUR
7/28/20250.14 EUR
Access this data via the Eulerpool API
Get Free API Key

Implanet Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
6.72 M EUR
-5.37 M EUR
-5.55 M EUR
Jan 1, 2019
7.41 M EUR
-3.43 M EUR
-3.65 M EUR
Jan 1, 2020
3.89 M EUR
-3.44 M EUR
-3.98 M EUR
Jan 1, 2021
6.14 M EUR
-4.64 M EUR
-3.09 M EUR
Jan 1, 2022
8.03 M EUR
-3.97 M EUR
-3.54 M EUR
Jan 1, 2023
7.45 M EUR
-4.80 M EUR
-6.68 M EUR
Jan 1, 2024
9.41 M EUR
-4.97 M EUR
-4.37 M EUR
Jan 1, 2025 (e)
20.60 M EUR
5,818.55 EUR
0.00 EUR

Implanet Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 26, 2026, 2:28 AM
 
REVENUEM EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
SHARESM
2010201120122013201420152016201720182019202020212022202320242025e
2.004.006.006.007.006.007.007.006.007.003.006.008.007.009.0020.00
–100.0050.00–16.67-14.2916.67–-14.2916.67-57.14100.0033.33-12.5028.57122.22
50.0025.0033.3333.3328.5733.3342.8642.8650.0057.1466.6750.0050.0057.1444.4444.44
1.001.002.002.002.002.003.003.003.004.002.003.004.004.004.008.89
-4.00-6.00-4.00-6.00-6.00-7.00-6.00-6.00-5.00-3.00-3.00-4.00-3.00-4.00-4.00–
-200.00-150.00-66.67-100.00-85.71-116.67-85.71-85.71-83.33-42.86-100.00-66.67-37.50-57.14-44.44–
-6.00-3.00-4.00-6.00-6.00-8.00-7.00-6.00-5.00-3.00-3.00-3.00-3.00-6.00-4.00–
–-50.0033.3350.00–33.33-12.50-14.29-16.67-40.00–––100.00-33.33–
31.3738.6441.994.540.190.300.460.580.751.713.078.5121.0339.87118.13118.13
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Implanet generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Implanet retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Implanet's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Implanet has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Implanet's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Implanet stock margins

The Implanet margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Implanet. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Implanet.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
55.57 %
-79.90 %
-82.60 %
Jan 1, 2019
55.99 %
-46.36 %
-49.21 %
Jan 1, 2020
65.60 %
-88.44 %
-102.16 %
Jan 1, 2021
60.59 %
-75.60 %
-50.29 %
Jan 1, 2022
61.80 %
-49.43 %
-44.10 %
Jan 1, 2023
56.83 %
-64.42 %
-89.65 %
Jan 1, 2024
53.05 %
-52.82 %
-46.42 %
Jan 1, 2025 (e)
53.05 %
0.03 %
0.00 %

Implanet Stock Revenue, EBIT, Earnings per Share

The Implanet earnings per share therefore indicates how much revenue Implanet has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2018
9.00 EUR
-7.19 EUR
-7.43 EUR
Jan 1, 2019
4.32 EUR
-2.00 EUR
-2.13 EUR
Jan 1, 2020
1.27 EUR
-1.12 EUR
-1.30 EUR
Jan 1, 2021
0.72 EUR
-0.55 EUR
-0.36 EUR
Jan 1, 2022
0.38 EUR
-0.19 EUR
-0.17 EUR
Jan 1, 2023
0.19 EUR
-0.12 EUR
-0.17 EUR
Jan 1, 2024
0.08 EUR
-0.04 EUR
-0.04 EUR
Jan 1, 2025 (e)
0.17 EUR
0.00 EUR
0.00 EUR

Implanet business model & stock analysis

Implanet SA is a French company that specializes in the manufacture and distribution of innovative medical products. The company was founded in 2007 by Ludovic Lastennet and Rémi Boyer and is headquartered in Bordeaux, France. Implanet's business model focuses on the development, production, and marketing of medical implants and instruments to support orthopedic surgeries. The company works closely with leading surgeons and healthcare facilities to find the ideal solution for patient needs. One of Implanet's main areas of expertise is the spine. The company develops various implantable products for the treatment of degenerative diseases such as scoliosis. Another important area for Implanet is orthopedics, where the company develops solutions for joint problems like knee or hip replacements. The company also creates customized implants tailored to each individual patient for maximum accuracy and effectiveness. A key aspect of Implanet's business model is adapting its products to meet customer requirements. The company collaborates closely with its customers to meet their specific needs and deliver the best possible solution. Implanet is committed to developing innovative solutions that align with surgeons' capabilities and cater to their needs. Implanet maintains partnerships and distribution agreements worldwide to sell its products and achieve market gains. The company distributes its products in the US, Europe, and Asia. To further expand its presence in these markets, Implanet collaborates closely with healthcare organizations and surgeons to ensure its products remain up-to-date and meet customer needs. Implanet strives to develop innovative solutions that revolutionize orthopedics and spine care. The company has already achieved significant success in the past with its Jazz technology, which serves as an excellent example of how the company operates in a customer-oriented and innovative manner. The Jazz technology is an implant designed for scoliosis treatment and is customized to each individual patient. Overall, Implanet has developed an innovative and customer-oriented business model that focuses on continuous product development and collaboration with surgeons and healthcare organizations. With a strong presence in the global market and a range of innovative products, the company positions itself as one of the leading providers in the field of spine care and orthopedics.

Implanet SWOT Analysis

Strengths

Implanet SA possesses several strengths that contribute to its success in the market:

  • Advanced medical technology: Implanet SA utilizes cutting-edge technology in developing its medical devices, providing it with a competitive advantage.
  • Strong research and development capabilities: The company invests heavily in R&D, enabling it to innovate and develop new products to meet market demands.
  • Established brand reputation: Implanet SA has built a strong brand image and is recognized for its quality and reliability in the medical industry.
  • Global presence: The company has a widespread global presence, allowing it to target diverse markets and customer bases.

Weaknesses

Despite its strengths, Implanet SA also faces certain weaknesses that can hinder its growth:

  • Limited product portfolio: The company's product range is relatively limited, which may restrict its ability to cater to varied customer needs.
  • High dependency on key customers: Implanet SA relies heavily on a few major customers, making it vulnerable to the loss of any significant contracts.
  • Financial constraints: The company may face financial challenges in funding its expansion plans and sustaining its operations.
  • Regulatory compliance: Compliance with stringent regulations in the medical industry can pose challenges and increase operational costs for Implanet SA.

Opportunities

Implanet SA can leverage various opportunities to enhance its business prospects:

  • Market expansion: There is a growing demand for advanced medical devices, particularly in emerging markets, providing Implanet SA with opportunities to penetrate new geographies.
  • Product diversification: The company can explore diversifying its product range to cater to a wider customer base and capitalize on emerging technologies.
  • Strategic partnerships: Collaborating with other industry players or healthcare institutions can enable Implanet SA to enhance its market reach and develop innovative solutions.
  • Changing demographics: The aging population and increasing healthcare needs create a favorable environment for Implanet SA to target a larger patient base.

Threats

Implanet SA faces several threats that may impact its business operations:

  • Intense competition: The medical device industry is highly competitive, with the presence of established players and new entrants vying for market share.
  • Technological advancements: Rapid technological advancements can make existing products obsolete and pose challenges for Implanet SA to stay ahead in the market.
  • Economic fluctuations: Economic uncertainties and downturns can impact healthcare spending, potentially affecting the demand for Implanet SA's products.
  • Regulatory changes: Frequent changes in healthcare regulations can impact the approval process, time to market, and overall compliance costs for Implanet SA.

Implanet Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Implanet historical P/E ratio, EBIT multiple, and P/S ratio

Implanet annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Implanet shares outstanding

The number of shares of Implanet was 118.13 M in 2025. This indicates how many shares Implanet is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2018
746,900.00 Stocks
Jan 1, 2019
1.71 M Stocks
Jan 1, 2020
3.07 M Stocks
Jan 1, 2021
8.51 M Stocks
Jan 1, 2022
21.03 M Stocks
Jan 1, 2023
39.87 M Stocks
Jan 1, 2024
118.13 M Stocks
Jan 1, 2025 (e)
118.13 M Stocks

Implanet stock splits

In Implanet's history, there have been no stock splits.

Current Implanet forecasts and price targets in July 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy88.89 % (8)
Hold11.11 % (1)
Sell0.00 % (0)
12M Price Target
2.00
Last Price
0.17
Currency
EUR
12M Return Potential
1,060.98 %
LTM Return
0 %

Implanet shareholder structure

% Name
78.87675%
Sanyou HK International Medical Holding Co Ltd
Sanyou HK International Medical Holding Co Ltd
0.72315%
Implanet SA Managers and Employees
Implanet SA Managers and Employees
0.00365%
Implanet SA Founders
Implanet SA Founders

Implanet Executives and Management Board

LL

Mr. Ludovic Lastennet

Chief Executive Officer, Director, Commercial Director · since 2013

Compensation294,000.00 EUR
ML

Mr. Mingyan Liu

Chairman of the Board

BL

Mr. Benjamin Letienne

Vice President of Marketing & International Sales, Director · since 2021

DF

Mr. David Fan

Director

NN

Ms. Nuan Ni

Director

Frequently asked questions about Implanet

The business model of Implanet SA focuses on providing innovative and advanced medical devices for orthopedic surgery. Implanet specializes in developing and marketing implant solutions for spinal surgery, enabling healthcare professionals to offer better patient care. Implanet SA's business model is centered around delivering cutting-edge technologies and solutions that improve surgical outcomes, enhance patient comfort, and reduce post-operative complications. The company's dedication to research, development, and collaboration with healthcare experts ensures the continuous advancement of implantable medical devices, making Implanet SA a key player in the orthopedic industry.

All fundamentals and in-depth analysis of Implanet

Our stock analysis for Implanet stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Implanet. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Implanet Stock
Implanet Revenue→
Implanet Stock
Implanet Net Income→
Implanet Stock
Implanet P/E→
Implanet Stock
Implanet P/S→
Implanet Stock
Implanet EBIT→
Implanet Stock
Implanet Dividend→
Implanet Stock
Implanet Directors Dealings→
Implanet Stock
Implanet Stocks→
Implanet Stock
Implanet Market capitalization→
Implanet Stock
Implanet Debt→
Implanet Stock
Implanet Liabilities→
Implanet Stock
Implanet Equity→
Implanet Stock
Implanet AAQS→
Implanet Stock
Implanet Employees→
Implanet Stock
Implanet ROE→
Implanet Stock
Implanet ROA→
Implanet Stock
Implanet ROCE→
Implanet Stock
Implanet News→
Implanet Stock
Implanet Analyst Price Targets→

Health Stocks

Improve Medical Instruments CoImpediMedImugeneImmutep Ltd ADRImunonImmutepIMVImmuron Ltd ADRIN8bioImmuronInBody CoImmunovia AB (publ)All Stocks A–Z →